Expression of mTOR protein and its clinical significance in endometrial cancer

Medical Science Monitor

Volumn 15, Issue 10, 2009, Pages

  Jae, Hong No ^a   Jeon, Yong Tark ^a   Park, In Ae ^a   Kang, Daehee ^a   Jae, Weon Kim ^a   Park, Noh Hyun ^a   Kang, Soon Beom ^a   Song, Yong Sang ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Endometrial cancer; Immunohistochemistry; mTOR

Indexed keywords

CYCLOOXYGENASE 2; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P53;

ADULT; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; MYOMETRIUM; OVERALL SURVIVAL; PROTEIN EXPRESSION;

AGED; CYCLOOXYGENASE 2; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEIN KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70349974719     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E et al: Cancer statistics, 2008. CA Cancer J Clin, 2008; 58: 71-96
2. Han SS, Cho JY, Park IA et al: Feasibility of routine lymphadenectomy in clinical stage-I endometrial cancer. Med Sci Monit, 2008; 14(4): CR183-89
3. Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell, 2000; 100: 387-390 (Pubitemid 30818176)
4. Chiang GG, Abraham RT: Targeting the mTOR signaling network in cancer. Trends Mol Med, 2007; 13: 433-442 (Pubitemid 47570021)
5. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N: mTOR, translation initiation and cancer. Oncogene, 2006; 25: 6416-6422
6. Morgensztern D, McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs, 2005; 16: 797-803 (Pubitemid 41215743)
7. Ruggero D, Pandolfi PP: Does the ribosome translate cancer? Nat Rev Cancer, 2003; 3: 179-192
8. Easton JB, Houghton PJ: mTOR and cancer therapy. Oncogene, 2006; 25: 6436-6446
9. Hudes G, Carducci M, Tomczak P et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med, 2007; 356: 2271-2281 (Pubitemid 46849157)
10. Jeon YT, Kang S, Kang DH et al: Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol Biomarkers Prev, 2004; 13: 1538-1542 (Pubitemid 39202324)
11. Vignot S, Faivre S, Aguirre D, Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol, 2005; 16: 525-537 (Pubitemid 40613318)
12. Zhou C, Gehrig PA, Whang YE, Boggess JF: Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther, 2003; 2: 789-795
13. Treeck O, Wackwitz B, Haus U, Ortmann O: Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol, 2006; 102: 292-299
14. Mutter GL, Lin MC, Fitzgerald JT et al: Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst, 2000; 92: 924-930
15. Kong D, Suzuki A, Zou TT et al: PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet, 1997; 17: 143-144
16. Corradetti MN, Guan KL: Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene, 2006; 25: 6347-6360
17. Leseux L, Hamdi SM, Al Saati T et al: Syk-dependent mTOR activation in follicular lymphoma cells. Blood, 2006; 108: 4156-4162 (Pubitemid 44913287)
18. Sieghart W, Fuereder T, Schmid K et al: Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation, 2007; 83: 425-432 (Pubitemid 46667846)
19. Panigrahi AR, Pinder SE, Chan SY et al: The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol, 2004; 204: 93-100
20. Slipicevic A, Holm R, Nguyen MT et al: Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol, 2005; 124: 528-536 (Pubitemid 41395633)
21. An HJ, Lee YH, Cho NH et al: Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology, 2002; 41: 437-445
22. Risinger JI, Hayes AK, Berchuck A, Barrett JC: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res, 1997; 57: 4736-4738
23. Pantuck AJ, Seligson DB, Klatte T et al: Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer, 2007; 109: 2257-2267 (Pubitemid 46801555)
24. Sansal I, Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol, 2004; 22: 2954-2963 (Pubitemid 41079915)
25. Terakawa N, Kanamori Y, Yoshida S: Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer, 2003; 10: 203-208 (Pubitemid 36758649)
26. Risinger JI, Hayes K, Maxwell GL et al: PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res, 1998; 4: 3005-3010 (Pubitemid 29001474)
27. St-Germain ME, Gagnon V, Mathieu I et al: Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells. Int J Oncol, 2004; 24: 1311-1324
28. Blanco-Aparicio C, Renner O, Leal JF, Carnero A: PTEN, more than the AKT pathway. Carcinogenesis, 2007; 28: 1379-1386 (Pubitemid 47243536)
29. Neeli I, Yellaturu CR, Rao GN: Arachidonic acid activation of translation initiation signaling in vascular smooth muscle cells. Biochem Biophys Res Commun, 2003; 309: 755-761 (Pubitemid 37122592)